Speaker

Dr. Hui during the COVID-19 pandemic, in collaboration with Germany’s BioNTech, actively participated in the research and development of the first mRNA product (mRNA COVID-19 vaccine Comirnaty/Fubitai) in human history, and led the research and development of the vaccine (Fubitai) in Greater China and its launch in Hong Kong, Macao and Taiwan; prompted the China’s mRNA industry. During his career, Dr. Hui has driven the global development and market approval of several anti-tumor blockbusters, including Ixazomib, Isatuximab, et al. In 2013, Dr. Hui pioneered the clinical registration model of ‘ Chinese extension study of global Phase III clinical trial’, substantially shorten the time span for innovative drugs in China. Dr. Hui published 100+ papers in prestigious journals including NEJM, Nature Med, Lancet Onco, Cancer Cell and Blood and authored 8 scientific monographies. Dr. Hui is the recipient of the 2021 International Award of the 4th Translational Medicine Awards among 20+ other prestigious awards. Dr. Hui is the former Executive President, Chair of the Scientific Committee, President of Global R&D and Chief Medical Officer of Fosun Pharma. Former Global Vice President of Sanofi，Director of the Shanghai Key Laboratory for Stem Cell Therapy.

Dr. Piers Ingram is the Chief Executive Officer and co-founder of Hummingbird Bioscience. Excited by the increasing pace of progress in systems biology and immunology, Piers co-founded the company in 2015 to better apply these advances to drug discovery and development. Prior to co-founding Hummingbird Bioscience, Piers spent 15 years in the biopharmaceutical industry in R&D consulting, commercial strategy and academia. Between 2013 and 2015, Piers was employed by Sanofi (NASDAQ: SNY) as Head of Strategic Planning, South East Asia, and between 2011 and 2013 at Monitor Group (and then Monitor Deloitte) as a Manager in the Strategy Consulting practice. Between 2008 and 2010, Piers was first a Research Fellow and then acting Research Group Head at the Centre for Integrative Systems Biology, Imperial College London. Piers holds an MSci in Mathematics, an MSc in Bioinformatics and a PhD in Systems Biology from Imperial College London, and an MBA from INSEAD.

Darren Ji is the Chairman and CEO of Elpiscience Biopharmaceuticals. He also serves as a board director at Legend Biotech (NASDAQ: LEGN). Previously, Darren was a Venture Partner at Lilly Asia Ventures (LAV), where he co-founded Elpiscience in 2017. Before that, Darren served as Global Head and Vice President of Roche Business Development for Asia and Emerging Markets. In this role, he led strategy and deal execution across more than 100 countries, championing and closing numerous key transactions. He managed a global team and built a strong business network in major markets, including China, Japan, Korea, Australia/New Zealand, Russia, and Brazil. A serial entrepreneur, Darren has a distinguished career spanning drug R&D and business development. He held leadership roles at Procter & Gamble and co-founded PharmaLegacy Laboratories, where he served as CEO. A highly respected figure in global life sciences, he is a sought-after speaker at industry forums and an active community builder. He was one of the longest board members of BayHelix Group, a community of life science business leaders of Chinese heritage. He currently serves on the Advisory Committee to BioCEO and Investor Conference. Darren holds an M.D. from China Medical University, a Ph.D. from the University of Sheffield, and an MBA from the University of Chicago.

Dr. Qunsheng Ji, the Chief Executive Officer of Sirius Therapeutics, is a seasoned pharmaceutical executive with near 30-year experience in drug discovery, translational medicine, and business leadership. Prior to Sirius Therapeutics, Dr. Ji was Vice President and Head of Oncology and Immunology Unit at WuXi AppTec, where he led team of over 1000 R&D personnel. Prior to WuXi AppTec, Dr. Ji was Head of Bioscience, Asia and Emerging Market iMed of AstraZeneca. He also served as Director of Translational Medicine, overseeing AstraZeneca’s global translational medicine portfolio. Dr. Ji started his industry career in the U.S where he worked at ONYX Pharmaceuticals and OSI Pharmaceuticals. Dr. Ji received his Ph.D. degrees in Cell Biology from Peking Union Medical College and Vanderbilt University in the U.S. He also received his Bachelors degree of Medicine in China, and is the author of more than 50 peer-reviewed research articles and book chapters.

A former researcher at the Shanghai Institute of Physiology, Chinese Academy of Sciences, Dr Ji Yong Hua is a recipient of the State Council Special Allowance and the National Outstanding Young Scientist Award. He holds a PhD in Pharmacy from Japan. In 1987, he served as a foreign researcher at the School of Medicine of the North Region of Marseille, France, and in 1997, he became a JSPS Special Research Fellow at Shizuoka Prefectural University, Japan. He has served as Secretary-General and Vice President of the Chinese Society of Neuroscience; three terms as Executive Director of the Chinese Biophysical Society; and concurrently served as a member of the National Committee of the Chinese People’s Political Consultative Conference (CPPCC) for three terms, an Executive Member of the All-China Federation of Trade Unions for two terms, and Vice Chairman of the Shanghai Citizens’ League for two terms. His interests focus on the neuropharmacology and toxicology of natural toxins, and he has published over 200 academic papers. He is currently a Distinguished Research Fellow at Hebei University.

Ms. Jiang Fan is primarily responsible for the company’s investment and financing, overall financial planning and analysis, and strategic planning. Ms. Jiang has over 15 years of experience in strategic consulting, investment, and financing within the pharmaceutical industry, with extensive experience in business strategy planning, transaction structuring, and portfolio development. Ms. Jiang holds a bachelor’s degree in biotechnology from Huazhong University of Science and Technology and an MBA from China Europe International Business School.

Dr. Gina Jiang is the Managing Director of the Hong Kong Institute of Biotechnology (HKIB), affiliated with The Chinese University of Hong Kong, where she has led the institute since April 2020. A key architect behind the development of a GMP-certified facility for Advanced Therapy Products, Dr. Jiang is accelerating the growth of cell and gene therapy capabilities in Hong Kong. Her international background spans leadership roles and entrepreneurial ventures in the San Francisco Bay Area and Taipei. She holds degrees from the University of Toronto and Peking University and conducted research at the NIH and Stanford University.

Dr. David Kin Jin is a Chinese-American scientist holding MD and PhD degrees from the United States, with clinical practice in Internal Medicine, Hematology, and Oncology. As a specially appointed chief medical expert at Shenzhen Cell Valley, he received clinical training and later became a professorship in Internal Medicine, Hematology, and Oncology at New York Presbyterian Hospital (a teaching hospital affiliated with Cornell and Columbia Universities). His career includes residency at Memorial Sloan Kettering Cancer Center (MSKCC), senior research fellowships and clinical directorships at the Ansary Stem Cell Institute of Cornell University School of Medicine and New York Presbyterian Hospital, former FDA Center for Drug Evaluation (CDER) review specialist, and Asia-Pacific special envoy for FACT International Cell Preparation Certification.

Dr. Yuanyuan Jin is the Co-Founder and Chief Executive Officer of Bound Therapeutics, a biotechnology company developing AI-driven RNA therapeutics with targeted delivery for treatment-resistant diseases. With over 15 years of expertise in RNA biology, drug delivery, and therapeutic development, she is advancing Bound’s mission to establish microRNA-targeted therapy as a new modality in oncology and beyond. Dr. Jin earned her PhD in Molecular Pharmacology and Structural Biology from Thomas Jefferson University, where she focused on microRNA-based therapeutics for cancer. At Bound, she leads the development of BND6482, a first-in-class miR-21 inhibitor that blocks multiple cancer survival pathways to overcome tumor resistance. Conjugated to a tumor-targeting peptide for selective delivery without lipid nanoparticles, BND6482 has shown superior efficacy and safety in aggressive cancer models. She also spearheads Bound’s proprietary Magic Bullet Designer™ (MBD) platform, which applies AI/ML to discover disease-specific delivery peptides. This innovation enables programmable RNA medicines with applications extending to CNS and fibrotic diseases. Before founding Bound, Dr. Jin contributed to RNA drug discovery across academia and biotech. At Bio Hong Kong, she will present how rational design and targeted delivery are unlocking the therapeutic potential of microRNAs, shaping the future of precision RNA medicine.

Dr. Erik Ko holds a BSc degree in Biochemistry and a PhD degree in Chinese Medicine from the Chinese University of Hong Kong. He has over 20 years of experience spanning academic research and commercial R&D, and specializes in advanced materials science and nanotechnology for TCM compound delivery enhancement. Dr. Ko has pioneered breakthrough material innovations including revolutionary water solubility platforms for insoluble natural compounds, rapid-release nanocarrier systems, and smart delivery matrices. Over the past five years, he has provided Hong Kong local industrial clients with R&D expertise, delivering actionable insights and value-added intelligence for different R&D challenges. His interdisciplinary expertise bridges ancient medicinal knowledge with modern materials engineering.